RxDoctor Payments Data

Desiree Levyim, MD

Neurology with Special Qualifications in Child Neurology · West Hills, CANPI 1497167985

Payments from drug & device makers

$5,529in general payments, 2019–2025

Across 245 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$605
  • Pfizer$569
  • Harmony Biosciences LLC$533
  • Novartis$371
  • Biohaven Pharmaceutical Holding Company Ltd.$348
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,515100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,529 in reported general payments places this provider in the 60th percentile of 216 neurology with special qualifications in child neurology providers in California.

See all neurology with special qualifications in child neurology providers in California

Medicare billing

Part B allowed, 2024
$122,975
Medicare patients
280
Services billed
2,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate49$73,260
QuliptaAtogepant29$30,761
RexultiBrexpiprazole17$24,601
RytaryCarbidopa/Levodopa13$4,567
Memantine Hcl ErMemantine Hcl42$3,998
Memantine Hcl105$3,463
Gabapentin161$2,189
Carbidopa-LevodopaCarbidopa/Levodopa58$1,388
Lidocaine18$1,375
Pregabalin74$1,264
Donepezil Hcl98$1,252
Entacapone12$1,177
Levetiracetam46$1,072
Quetiapine Fumarate53$950
Primidone68$947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$569$73,26049 claims
AbbVieQulipta$1,040$30,76129 claims
Amneal Pharmaceuticals LLCRytary$24$4,56713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 216 neurology with special qualifications in child neurology providers in California.

Other neurology with special qualifications in child neurology in West Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →